Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Michaelson

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
The American Journal of Cardiology|May 22, 1997
Use of calcium antagonists in patients with ischemic heart disease and systemic hypertensionW H Frishman, M D Michaelson
Journal of Clinical Pharmacology|June 1, 1997
The pharmacologic approach to the treatment of obesityM Weiser, W H Frishman, M D Michaelson, et al.
Developmental Biology|October 10, 1996
Interleukin-7 is trophic for embryonic neurons and is expressed in developing brainM D Michaelson, M F Mehler, H Xu, et al.
British Journal of Cancer|February 5, 2004
Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladderM D Michaelson, W U Shipley, N M Heney, et al.
British Journal of Cancer|January 14, 2012
Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinomaD Cella, A G Bushmakin, J C Cappelleri, et al.
Vision Research|January 13, 1998
Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acidD M Rosenbaum, P S Rosenbaum, A Gupta, et al.
Development (Cambridge, England)|September 1, 1996
CSF-1 deficiency in mice results in abnormal brain developmentM D Michaelson, P L Bieri, M F Mehler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2010
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinomaS Patil, R A Figlin, T E Hutson, et al.
British Journal of Cancer|May 10, 2012
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-αS Patil, R A Figlin, T E Hutson, et al.
British Journal of Cancer|January 28, 2010
Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysisD Cella, M D Michaelson, A G Bushmakin, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The American Journal of Cardiology|May 22, 1997
Use of calcium antagonists in patients with ischemic heart disease and systemic hypertensionW H Frishman, M D Michaelson
Journal of Clinical Pharmacology|June 1, 1997
The pharmacologic approach to the treatment of obesityM Weiser, W H Frishman, M D Michaelson, et al.
Developmental Biology|October 10, 1996
Interleukin-7 is trophic for embryonic neurons and is expressed in developing brainM D Michaelson, M F Mehler, H Xu, et al.
British Journal of Cancer|February 5, 2004
Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladderM D Michaelson, W U Shipley, N M Heney, et al.
British Journal of Cancer|January 14, 2012
Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinomaD Cella, A G Bushmakin, J C Cappelleri, et al.
Vision Research|January 13, 1998
Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acidD M Rosenbaum, P S Rosenbaum, A Gupta, et al.
Development (Cambridge, England)|September 1, 1996
CSF-1 deficiency in mice results in abnormal brain developmentM D Michaelson, P L Bieri, M F Mehler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2010
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinomaS Patil, R A Figlin, T E Hutson, et al.
British Journal of Cancer|May 10, 2012
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-αS Patil, R A Figlin, T E Hutson, et al.
British Journal of Cancer|January 28, 2010
Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysisD Cella, M D Michaelson, A G Bushmakin, et al.
Pageof 2